Mammary tumour inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednisolone.
Prednimustine, a chlorambucil ester of pregnisolone, retarded growth of DMBA-induced mammary tumours in rats and reduced the number of tumours. A combination of chlorambucil and prednisolone (C + P) in the same proportion as in prednimustine, had similar effects, 8 and 26 mg per kg of the C + P combination being equipotnet to 16 and 64 mg per kg of prednimustine, respectively. The mortality figures suggested that prednimustine was considerably less toxic than equipotent doses of C + P. This toxicity difference was confirmed in a parallel investigation of the subacute toxicity in rats of prednimustine and C + P. This study showed that the mortality, reduction of lymphocytes and platelets, and bone marrow depression was much lower after pregnimustine than after equimolar amounts of the C + P combination. The results suggest that the low toxicity of prednimustine makes this drug a better cytostatic agent than the C + P combination treatment.
D000818:Animals; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D008214:Lymphocytes / Q000187:drug effects; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats
D004338:Drug Combinations; D002699:Chlorambucil; D011239:Prednisolone